CrystEngComm (2009), 11, 791

​A. Portell, R. Barbas, M. Font-Bardia, P. Dalmases, R. Prohens, C. Puigjaner, CrystEngComm, 11, 791-795, 2009
​Ziprasidone, an antipsychotic agent used in the treatment of schizophrenia, is marketed either as an oral capsule (containing the monohydrate hydrochloride salt of the API) or as an injectable drug (ziprasidone mesylate trihydrate). The drug is poorly soluble in water which adversely effects the bioavailability. This study reports a new salt of ziprasidone (malate salt), which exhibits three different polymorphic crystal forms. One of the polymorphs of the malate salt shows the highest solubility ever reported for ziprasidone (14-fold better than the marketed hydrochloride salt).

Cryst.Growth Des. (2009), 9, 3918

​L. Renou, S. Coste, Y. Cartigny, M.-N. Petit, C. Vincent, J.-M. Schneider, G. Coquerel, Cryst. Growth Des., 9, 3918–3927, 2009.
​The monohydrate and anhydrous crystal forms of the antifungal agent ciclopirox ethanolamine (1:1) are reported. It is determined that, under normal conditions, the dehydration of the 1:1 ciclopirox ethanolamine monohydrate structure leads to a 2:1 ciclopirox ethanolamine form through a destructive mechanism. Under saturated ethanolamine vapour pressure, however, the dehydration/hydration mechanism is reversible for up to two cycles without degradation of the 1:1 compound. The study suggests that under normal conditions the 2:1 ciclopirox ethanolamine form is the most stable.